CLVS Historical PE Ratio image   This CLVS PE ratio history page last updated 11/10/2022
CLVS PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/9/2022
0.28-0.39-1.81NA
Q2 2022
8/8/2022
1.45-0.50-1.98NA
Q1 2022
5/4/2022
1.68-0.44-2.07NA
Q4 2021
2/23/2022
1.62-0.48-2.27NA
Q3 2021
11/3/2021
4.69-0.56-2.53NA
Q2 2021
8/4/2021
4.82-0.59-2.86NA
Q1 2021
5/5/2021
5.86-0.64-3.38NA
Q4 2020
2/23/2021
6.01-0.74-4.02NA
Q3 2020
11/5/2020
4.47-0.89-5.09NA
Q2 2020
8/6/2020
6.23-1.11-6.05NA
Q1 2020
5/5/2020
7.71-1.28-6.74NA
Q4 2019
2/24/2020
9.92-1.81-7.09NA
Q3 2019
11/7/2019
4.32-1.85-7.16NA
Q2 2019
8/1/2019
8.87-1.80-7.02NA
Q1 2019
5/7/2019
19.46-1.63-6.77NA
Q4 2018
2/26/2019
26.05-1.88-6.68NA
Q3 2018
10/30/2018
16.61-1.71-6.07NA
Q2 2018
8/1/2018
46.01-1.55-5.60NA
Q1 2018
5/8/2018
42.61-1.54-5.34NA
Q4 2017
2/26/2018
55.51-1.27-5.13NA
Q3 2017
11/1/2017
72.86-1.24-5.69NA
Q2 2017
8/2/2017
81.61-1.29-6.15NA
Q1 2017
5/3/2017
53.30-1.33-6.93NA
Q4 2016
2/22/2017
61.19-1.83-7.77NA
Q3 2016
11/3/2016
25.90-1.70-8.17NA
Q2 2016
8/8/2016
15.69-2.07-9.09NA
Q1 2016
5/5/2016
12.66-2.17-9.12NA
Q4 2015
2/25/2016
17.29-2.23-8.81NA
Q3 2015
11/5/2015
103.55-2.62-8.20NA
Q2 2015
8/6/2015
83.17-2.10-6.75NA
Q1 2015
5/6/2015
79.91-1.86-5.68NA
Q4 2014
2/25/2015
76.55-1.62-4.73NA
Q3 2014
11/6/2014
58.57-1.17-4.03NA
Q2 2014
8/7/2014
36.88-1.03-3.54NA
Q1 2014
5/8/2014
49.32-0.91-3.23NA
Q4 2013
2/27/2014
78.38-0.92-2.92NA
Q3 2013
10/31/2013
51.11-0.68-2.85NA
Q2 2013
8/1/2013
77.36-0.72-2.88NA
Q1 2013
5/7/2013
33.01-0.60NANA
Q4 2012
2/28/2013
18.86-0.85NANA
Q3 2012
11/5/2012
22.37-0.71NANA
CLVS Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/9/2022
0.28-0.39-1.56NA
Q2 2022
8/8/2022
1.45-0.50-2.00NA
Q1 2022
5/4/2022
1.68-0.44-1.76NA
Q4 2021
2/23/2022
1.62-0.48-1.92NA
Q3 2021
11/3/2021
4.69-0.56-2.24NA
Q2 2021
8/4/2021
4.82-0.59-2.36NA
Q1 2021
5/5/2021
5.86-0.64-2.56NA
Q4 2020
2/23/2021
6.01-0.74-2.96NA
Q3 2020
11/5/2020
4.47-0.89-3.56NA
Q2 2020
8/6/2020
6.23-1.11-4.44NA
Q1 2020
5/5/2020
7.71-1.28-5.12NA
Q4 2019
2/24/2020
9.92-1.81-7.24NA
Q3 2019
11/7/2019
4.32-1.85-7.40NA
Q2 2019
8/1/2019
8.87-1.80-7.20NA
Q1 2019
5/7/2019
19.46-1.63-6.52NA
Q4 2018
2/26/2019
26.05-1.88-7.52NA
Q3 2018
10/30/2018
16.61-1.71-6.84NA
Q2 2018
8/1/2018
46.01-1.55-6.20NA
Q1 2018
5/8/2018
42.61-1.54-6.16NA
Q4 2017
2/26/2018
55.51-1.27-5.08NA
Q3 2017
11/1/2017
72.86-1.24-4.96NA
Q2 2017
8/2/2017
81.61-1.29-5.16NA
Q1 2017
5/3/2017
53.30-1.33-5.32NA
Q4 2016
2/22/2017
61.19-1.83-7.32NA
Q3 2016
11/3/2016
25.90-1.70-6.80NA
Q2 2016
8/8/2016
15.69-2.07-8.28NA
Q1 2016
5/5/2016
12.66-2.17-8.68NA
Q4 2015
2/25/2016
17.29-2.23-8.92NA
Q3 2015
11/5/2015
103.55-2.62-10.48NA
Q2 2015
8/6/2015
83.17-2.10-8.40NA
Q1 2015
5/6/2015
79.91-1.86-7.44NA
Q4 2014
2/25/2015
76.55-1.62-6.48NA
Q3 2014
11/6/2014
58.57-1.17-4.68NA
Q2 2014
8/7/2014
36.88-1.03-4.12NA
Q1 2014
5/8/2014
49.32-0.91-3.64NA
Q4 2013
2/27/2014
78.38-0.92-3.68NA
Q3 2013
10/31/2013
51.11-0.68-2.72NA
Q2 2013
8/1/2013
77.36-0.72-2.88NA
Q1 2013
5/7/2013
33.01-0.60-2.40NA
Q4 2012
2/28/2013
18.86-0.85-3.40NA
Q3 2012
11/5/2012
22.37-0.71-2.84NA
Quotes delayed 20 minutes

Email EnvelopeFree CLVS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Clovis Oncology (CLVS) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CLXT PE Ratio History
CMAX PE Ratio History
CMD PE Ratio History
CMPI PE Ratio History
CMPX PE Ratio History
CMRX PE Ratio History
CNC PE Ratio History
CNCE PE Ratio History
CNMD PE Ratio History
CNSP PE Ratio History
On this page we presented the CLVS PE Ratio History information for Clovis Oncology' stock. The average CLVS PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CLVS PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CLVS PE ratio history result, against the recent PE: when this page was posted on 11/9/2022, the most recent closing price for CLVS had been 0.28, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CLVS or any other given stock, valuation analysis for CLVS can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Clovis Oncology PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for CLVS. Thanks for visiting, and the next time you need to research CLVS PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: Institutional Holders of EQH, PXD Historical Stock Prices, DOMO Videos.

 

CLVS PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.